Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Heart ; 90(1): e2, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14676265

ABSTRACT

The case of a 14 month old girl with primary pulmonary hypertension treated with domiciliary oxygen is described. After invasive evaluation and testing of nitric oxide with very good response, the testing was repeated to study the effect of inhaled iloprost on pulmonary vascular resistance (PVR). An unexpected and severe increase of PVR was observed, rising from 392 dynes x s x cm(-5) with oxygen to a maximum of 1192 dynes x s x cm(-5) with oxygen and iloprost. Underlying ventilatory and technical problems were excluded. While inhaled iloprost has been described to be highly effective in the treatment of primary pulmonary hypertension, the possibility of contrary "paradoxical" reactions in isolated patients is emphasised, with a dramatic increase of PVR and a possible adverse outcome.


Subject(s)
Hypertension, Pulmonary/physiopathology , Iloprost/adverse effects , Vascular Resistance/drug effects , Vasodilator Agents/adverse effects , Administration, Inhalation , Blood Pressure/drug effects , Female , Humans , Infant
2.
Pediatr Nephrol ; 12(1): 16-9, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9502560

ABSTRACT

Joubert syndrome type B (JSB) is a developmental disorder of the nephronophthisis (NPH) complex with multiple organ involvement, including NPH, coloboma of the eye, aplasia of the cerebellar vermis, and the facultative symptoms of psychomotor retardation, polydactyly, and neonatal tachypnea. In isolated autosomal recessive NPH type 1 (NPH1), homozygous deletions have been described as causative in more than 80% of patients. Since different combinations of the extrarenal symptoms with NPH occur in JSB, a contiguous gene deletion syndrome in the NPH1 genetic region would seem a highly likely cause for JSB. We therefore examined 11 families with JSB for the presence of extended deletions at the NPH1 locus. Genomic DNA was examined using four consecutive polymerase chain reaction (PCR) markers that are deleted in NPH1 and three PCR makers flanking the NPH1 deletion. In all seven markers examined, there was no homozygous deletion detected in any of the 11 JSB families studied. Since these markers saturate the NPH1 deletion region at high density, this finding excludes the presence of large homozygous deletions of the NPH1 region in these JSB families, making it unlikely that deletions of the NPH1 region are a primary cause for JSB.


Subject(s)
Cerebellar Diseases/genetics , Cerebellum/abnormalities , Gene Deletion , Child , DNA/analysis , Genetic Markers , Homozygote , Humans , Polymerase Chain Reaction , Syndrome
3.
Eur J Pediatr ; 155(11): 963-7, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8911898

ABSTRACT

UNLABELLED: We report six patients with aplasia or hypoplasia of the cerebellar vermis with early symptoms consisting of psychomotor retardation, nystagmus and severely reduced visual acuity due to congenital amaurosis. At age 5.6-12.1 years, five of these patients developed symptoms of chronic renal failure due to renal maldevelopment. CONCLUSION: Children presenting with vermis aplasia should be monitored for associated disorders, especially renal disease.


Subject(s)
Cerebellum/abnormalities , Kidney Failure, Chronic/etiology , Blindness/etiology , Child , Child, Preschool , Humans , Intellectual Disability/complications , Kidney Failure, Chronic/complications , Nystagmus, Pathologic/etiology , Psychomotor Disorders/etiology , Syndrome
4.
Nephrol Dial Transplant ; 11(3): 468-73, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8671817

ABSTRACT

BACKGROUND: Pneumococcal vaccination has been recommended for immunocompromised children over 2 years including patients with chronic renal disease. However, the effect of vaccination and revaccination is variable and the indication for immunization is a subject of controversy. METHODS: Forty children and young adults with chronic renal diseases (including the idiopathic nephrotic syndrome, chronic renal failure, patients undergoing dialysis and after transplantation) were vaccinated with a 23-valent pneumococcal vaccine. The efficacy of the vaccine was evaluated by measuring antibody titres before and 4 weeks, 6 months, and 12 months after vaccination. Twenty-two patients were submitted to a revaccination 1 year after the first vaccination. RESULTS: A sufficient immune response, defined as an at least fourfold increase of postvaccinal antibody titres and an antibody titre > 200, was observed in 83% of the patients 4 weeks after vaccination, but only in 68% after 6 months, and in 48% after 1 year. Revaccination produced a significant immune response in 11/22 patients (50%) followed by a rapid decline of antibody levels within 6 months. Both vaccinations were well tolerated. CONCLUSIONS: The currently available vaccine is without major side-effects and effective in producing a significant immune response. Antibody levels should be monitored in vaccinated patients with chronic renal diseases considering the rapid decline as early as 6 months after vaccination. Evaluation of the efficacy of revaccination in these patients requires further investigations.


Subject(s)
Bacterial Vaccines/administration & dosage , Kidney Failure, Chronic/complications , Pneumococcal Infections/prevention & control , Streptococcus pneumoniae/immunology , Vaccination/methods , Adolescent , Adult , Antibodies, Bacterial/analysis , Bacterial Vaccines/adverse effects , Child , Child, Preschool , Follow-Up Studies , Humans , Immunization, Secondary , Kidney Failure, Chronic/immunology , Pneumococcal Infections/complications , Pneumococcal Infections/immunology , Pneumococcal Vaccines
SELECTION OF CITATIONS
SEARCH DETAIL
...